Get the Stockscreener App
0.7551
0.93%
0.0051
Tscan Therapeutics Inc stock is traded at $0.7551, with a volume of 209.75K.
It is up +0.93% in the last 24 hours and down -18.13% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.75
Open:
$0.75
24h Volume:
209.75K
Relative Volume:
0.35
Market Cap:
$51.24M
Revenue:
$9.14M
Net Income/Loss:
$-124.31M
P/E Ratio:
-0.7888
EPS:
-0.9573
Net Cash Flow:
$-125.43M
1W Performance:
-1.94%
1M Performance:
-18.13%
6M Performance:
-25.05%
1Y Performance:
-55.47%
1-Day Range:
$0.75
$0.77
1-Week Range:
$0.741
$0.838
52-Week Range:
$0.716
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.756 | 50.83M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
543.57 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.69 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,036.30 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
131.31 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.24 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
TScan Therapeutics Faces Loss of Key Amgen Partnership - TipRanks
TScan TherapeuticsAmgen To Terminate Research Collaboration And License Agreement With TScan TherapeuticsSEC Filing - TradingView
TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration - Stock Titan
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - Kalkine
TScan Therapeutics (TCRX) Edges Higher, Holding Support at $0.74Up Down Volume - Vinanet
Lynx1 Capital discloses 13.1% position in TScan Therapeutics (TCRX) common stock - Stock Titan
Biotechnology Value Fund group (TCRX) reports 9.99% TScan ownership with large warrants - Stock Titan
Equities Analysts Set Expectations for TCRX FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy - Investing.com
Tscan Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
TScan Therapeutics, Inc. (TCRX) stock price, news, quote and history - uk.finance.yahoo.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Releases Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
TScan Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
TScan Therapeutics, Inc. (TCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TScan Therapeutics Q2 Results: Sales Fall 66% YoY, EPS Misses - scanx.trade
TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Form 8K Tscan Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
TScan Therapeutics, Inc. 2Q 2026: Revenue $1.05M, Net loss $30.36M, EPS $(0.23) — 10-Q Summary - TradingView
TScan Therapeutics (TCRX) narrows loss but warns on going-concern outlook and debt - Stock Titan
TScan Therapeutics reports Q2 2026: $1.1M revenue, $30.4M net loss, cash $100.2M - TradingView
TScan Therapeutics Reports $30.4 Million Q2 Net Loss - Quiver Quantitative
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
TScan Therapeutics (TCRX) narrows Q2 2026 loss and doses first patient in Phase 3 ALLOHA-2 trial - Stock Titan
TScan Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results - Quiver Quantitative
TScan Q2 FY26 net loss narrows to $30.4 million; revenue drops to $1.1 million - Bitget
TScan Therapeutics (TCRX) Edges Higher as Price Holds Above Key $0.73 SupportIndex Put Call - Vinanet
TScan Therapeutics Inc (TCRX) Stock News Today - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
TScan Therapeutics (TCRX) Climbs 4.5% to $0.77, Testing Key Resistance ZoneSweep Order Flow - Vinanet
Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 95.5% - MarketBeat
TScan doses first patient in phase 3 AML, MDS trial By Investing.com - Investing.com Nigeria
TScan Therapeutics Announces First Patient Dosed in Phase 3 - GlobeNewswire
TScan’s Phase 3 Cancer Trial Enrolls Across U.S.; Data Expected 2028 - Stock Titan
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Income Statement - TradingKey
TScan Therapeutics Inc (TCRX) Cash Flow - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.765|Chg%:-0.029 - TradingKey
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Balance Sheet - TradingKey
TScan Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):